Darbepoetin alfa in lung cancer patients on chemotherapy: A retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline

Supportive Care in Cancer

Volumn 12, Issue 4, 2004, Pages 253-262

  Vansteenkiste, J ^a   Tomita, D ^b   Rossi, G ^b   Pirker, R ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b AMGEN INC   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anaemia; Darbepoetin alfa; Erythropoietin; Lung cancer; Transfusion

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHI-SQUARE DISTRIBUTION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FATIGUE; FEMALE; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLACEBOS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 2442716204     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0583-0     Document Type: Article

References (27)

1. Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A:S2-S8
2. Amgen (2001) Aranesp package insert. Amgen Europe, Breda, The Netherlands
3. Amgen (2002) Aranesp (darbepoetin alfa). Prescribing information. Amgen, Thousand Oaks, CA
4. Barrett-Lee PJ, Bailey NP, O'Brien MER, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82:93-97
5. Cella D, Eton DT, Lai J-S, et al (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547-561
6. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P (2001) Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37:1617-1623
7. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412-3425
8. European Agency for Evaluation of Medicinal Products (2001) European Public Assessment Report (EPAR). Aranesp, Summary of Product Characteristics. European Union
9. Gabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhorn L (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882
10. Glaser CM, Millesi W, Kornek GV, et al (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705-715
11. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234
12. Glaspy JA, Jadeja JS, Justice G, et al (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268-276
13. Grogan M, Thomas GM, Melamed I, et al (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86:1528-1536
14. Hedenus M, Hansen S, Taylor K, et al (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79-86
15. Kotasek D, Albertsson M, Mackey J, et al (2002) Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3 W) or 4 (Q4 W) weeks in patients with solid tumors (abstract). Proc Am Soc Clin Oncol 21:356a
16. Lee WR, Berkey B, Marcial V, et al (1998) Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42:1069-1075
17. Littlewood TJ, Bajetta E, Nortier J, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind placebo-controlled trial. J Clin Oncol 19:2865-2874
18. Ludwig H, Strasser K (2001) Symptomatology of anemia. Semin Oncol 28:7-14
19. National Comprehensive Cancer Network (2003) NCCN Practice Guidelines in Oncology-Cancer and Treatment-related Anemia, version 1.2003. http//www.nccn.org/physician_gls/f_ guidelines.html
20. Ortega A, Dranitsaris G, Puodziunas AL (1998) A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Health Care 14:788-798
21. Pirker R, Vansteenkiste J, Tomita D, Rossi G, Colowick A, Musil J (2002) Exploratory analysis of the effect of baseline hemoglobin (Hb) on response to darbepoetin alfa in a phase 3 study in lung cancer patients (pts) (abstract). Ann Oncol 13 [Suppl 5]:177
22. Quirt I, Robeson C, Lau CY, et al (2001) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126-4134
23. Rizzo JD, Lichtin AE, Woolf SH, et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303-2320
24. Seidenfeld J, Piper M, Flamm C, et al (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204-1214
25. Smith R, Tchekmedyian NS, Richards D, et al (2002) Darbepoetin alfa effectively alleviates anemia in patients with chronic anemia of cancer: efficacy and pharmacokinetic results of a dose-escalation study (abstract). Proc Am Soc Clin Oncol 21:367a
26. Vansteenkiste J, Pirker R, Massuti B, et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220
27. Wurnig C, Windhager R, Schwameis E, et al (1996) Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 36:155-159